Literature DB >> 23580706

Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone.

Esther Viedma1, Carlos Juan, Joaquín R Otero, Antonio Oliver, Fernando Chaves.   

Abstract

The VIM-2-producing multidrug-resistant high-risk clone Pseudomonas aeruginosa sequence type (ST) 175 was isolated in the setting of a large outbreak in Hospital Universitario 12 de Octubre (Spain) from 2007 to 2010. This strain was resistant to all β-lactams, fluoroquinolones, and aminoglycosides, with the exception of amikacin, and has become an endemic clone in our institution.

Entities:  

Year:  2013        PMID: 23580706      PMCID: PMC3624680          DOI: 10.1128/genomeA.00112-13

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Pseudomonas aeruginosa is among the most relevant nosocomial pathogens, frequently causing severe infections in immunocompromised and critically ill patients, due to its ubiquitous nature, ability to colonize and survive in hospital reservoirs, and remarkable intrinsic antibiotic resistance and virulence (1). The versatility of P. aeruginosa to combine mutation-driven and horizontally acquired resistance mechanisms has led to the emergence of strains that are resistant to nearly all antimicrobials, dramatically compromising our therapeutic options to treat the infections caused by these pathogens (2, 3). Particularly concerning are the increasing reports of outbreaks, in multiple hospitals from several countries, of strains producing metallo-β-lactamases (MBL), with VIM-2 being the dominant MBL variant in Spain and worldwide (4–7). Moreover, most of these outbreaks are caused by a very limited number of P. aeruginosa genotypes, denominated international high-risk clones (8). Thus, deciphering the genetic determinants driving the success of these clones is crucial for the establishment of control and treatment strategies. The P. aeruginosa strain PA21_ST175 was isolated from a blood culture in the setting of a large outbreak by a VIM-2-producing multidrug-resistant P. aeruginosa clone. The outbreak affected a total of 104 patients and persisted in our hospital for at least 34 months despite the control measures that were implemented. This strain was responsible for over half of the infections or colonizations by multidrug-resistant P. aeruginosa from 2007 to 2010, reaching 76% in the last year of the period studied (9). Moreover, it belonged to the international high-risk clone of sequence type (ST) 175 and was resistant to all beta-lactams, fluoroquinolones, and aminoglycosides, with the exception of amikacin. Particularly noteworthy, the strain produced a VIM-2 MBL and an aminoglycoside-modifying enzyme (AAC6′Ib) located in a class I integron (9). Whole-genome shotgun sequencing was performed using a Roche 454 Junior sequencer. A total of 164,273,685 bp was obtained from Roche 454, providing approximately 22-fold coverage and 368,892 reads, with a G+C content of 66.1%. Sequences obtained were used for de novo assembly using Newbler Assembler v2.7 (Roche). The draft genome sequence consists of 100 contigs with an N50 contig size of 278,105 nucleotides and a total length of 6,889,935 bp. Sequences were annotated using the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) (http://www.ncbi.nlm.nih.gov/) and the Rapid Annotations using Subsystems Technology (RAST) server (10), yielding a total of 6,488 coding DNA sequence (CDS) genes and 58 tRNAs. This approach highlighted the presence of up to 152 genes related to antibiotic and antiseptic resistance, including the previously characterized blaVIM-2. Several chromosomal mutations involved in antibiotic resistance, including many of those previously reported for other ST175 lineages (11), were also detected. Ongoing comparative genomic analysis with other widespread high-risk clones, such as ST111 or ST235 (12), and nonepidemic multidrug-resistant strains will help to elucidate the secret of the success of these international multidrug-resistant clonal lineages, a crucial step in the establishment of global control and treatment strategies to combat them.

Nucleotide sequence accession number.

The draft genome sequence of P. aeruginosa ST175 has been included in the GenBank Whole-Genome Shotgun (WGS) database under the accession no. AOIH00000000.
  12 in total

1.  First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Authors:  K Lolans; A M Queenan; K Bush; A Sahud; J P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.

Authors:  Esther Viedma; Carlos Juan; Joshi Acosta; Laura Zamorano; Joaquín R Otero; Francisca Sanz; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

4.  National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 5.  Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.

Authors:  Neil Woodford; Jane F Turton; David M Livermore
Journal:  FEMS Microbiol Rev       Date:  2011-03-01       Impact factor: 16.408

6.  The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.

Authors:  L Leibovici; I Shraga; M Drucker; H Konigsberger; Z Samra; S D Pitlik
Journal:  J Intern Med       Date:  1998-11       Impact factor: 8.989

7.  Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

Authors:  Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Juan F Gago; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

8.  Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications.

Authors:  C Peña; C Suarez; F Tubau; O Gutierrez; A Domínguez; A Oliver; M Pujol; F Gudiol; J Ariza
Journal:  Clin Microbiol Infect       Date:  2007-07-25       Impact factor: 8.067

9.  VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain.

Authors:  Esther Viedma; Carlos Juan; Jennifer Villa; Laura Barrado; M Angeles Orellana; Francisca Sanz; Joaquín R Otero; Antonio Oliver; Fernando Chaves
Journal:  Emerg Infect Dis       Date:  2012-08       Impact factor: 6.883

10.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

View more
  5 in total

1.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Comparison of local features from two Spanish hospitals reveals common and specific traits at multiple levels of the molecular epidemiology of metallo-β-lactamase-producing Pseudomonas spp.

Authors:  Esther Viedma; Vanesa Estepa; Carlos Juan; Jane Castillo-Vera; Beatriz Rojo-Bezares; Cristina Seral; Francisco Javier Castillo; Yolanda Sáenz; Carmen Torres; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

3.  Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain.

Authors:  Esther Viedma; Jenifer Villa; Carlos Juan; Antonio Oliver; Fernando Chaves
Journal:  Genome Announc       Date:  2014-10-30

4.  Virulence Characteristics and an Action Mode of Antibiotic Resistance in Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Wontae Hwang; Sang Sun Yoon
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

5.  Antibiotic resistance pattern and evaluation of metallo-beta lactamase genes (VIM and IMP) in Pseudomonas aeruginosa strains producing MBL enzyme, isolated from patients with secondary immunodeficiency.

Authors:  Kiana Shirani; Behrouz Ataei; Fardad Roshandel
Journal:  Adv Biomed Res       Date:  2016-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.